Role of istradefylline for treating Parkinson’s disease

Alhashmi, Hadeel Ali Abdelsalam (2020-02-20)

Parkinson’s disease (PD) is the second-most common neurodegenerative disorder after Alzheimer’s disease. It slowly progressive neurodegenerative disease results from reduction of dopaminergic activity in nigrostriatal pathway1 . The Parkinson is not the same for everyone, each person has unique and different symptoms. It affects about 4 million people worldwide, and this number is expected to double by the year 20302 . The stages of PD depend on both severity of movement symptoms and how much the disease affects a person’s daily activities3 . The causes of PD stay unknown may be due to combination of genetic and environmental factors

Other

This report evaluated the efficacy and safety of istradefylline in Parkinson’s disease patients with wearing-off symptoms and dyskinesia. Parkinson’s disease (PD) is the second-most common neurodegenerative disorder after Alzheimer’s disease. It slowly progressive neurodegenerative disease results from reduction of dopaminergic activity in nigrostriatal pathway. Istradefylline is non-dopaminergic, selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease (PD) in patients with wearing-off symptoms and dysknisia with levodopa (L-DOPA) therapy. Istradefylline safety was assessed by the incidence of treatment emergency adverse effects (TEAEs) and drug-related TEAEs. Effectiveness was assessed off-time, off-time symptoms, ON-time with dyskinesia and ON-time without dyskinesia. The change in daily OFF time duration was significantly reduced in the istradefylline 20 mg/day and istradefylline 40 mg/day groups. In the long term study that conducted in 2015 the most frequently TEAE was nasopharyngitis, and the most frequently drug-related TEAE was dyskinesia compared with the the study conducted between 2009 and 2011. istradefylline administered as adjunctive therapy to levodopa was safe and produced a sustained reduction in off time and further improved motor functions during on state in advanced Parkinson’s Disease (PD) patients

Collections:
Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States